<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614988</url>
  </required_header>
  <id_info>
    <org_study_id>180209</org_study_id>
    <nct_id>NCT03614988</nct_id>
  </id_info>
  <brief_title>Evaluation of Evening Versus Morning Levothyroxine Intake in Elderly</brief_title>
  <acronym>MONIALE</acronym>
  <official_title>Comparative Evaluation of Evening Versus Morning Levothyroxine Administration in Treatment of Hypothyroidism in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study designed to compare evening versus morning levothyroxine intake in the elderly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized crossover trial of two dosing strategies for pharmacological treatment
      of hypothyroidism in a sample of individuals aged 60 years or older, performed at an
      outpatient healthcare in a tertiary center.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in TSH (Thyroid-Stimulating Hormone) levels.</measure>
    <time_frame>24 weeks.</time_frame>
    <description>Variation in TSH (Thyroid-Stimulating Hormone) levels after 24 weeks of levothyroxine use in the evening compared to the morning period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of drugs with potential drug interaction with levothyroxine.</measure>
    <time_frame>24 weeks</time_frame>
    <description>To identify the major medications that interfere with the absorption of levothyroxine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of TSH (Thyroid-Stimulating Hormone) control in each group.</measure>
    <time_frame>24 weeks</time_frame>
    <description>To compare the TSH (Thyroid-Stimulating Hormone) control efficacy between the two treatment strategies in this subgroup of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSH (Thyroid-Stimulating Hormone) levels of the patients at baseline</measure>
    <time_frame>Baseline (0 weeks)</time_frame>
    <description>To assess the TSH (Thyroid-Stimulating Hormone) levels in this sample of patients at the time of study inclusion, in order to evaluate their real life in terms of adherence and relation with polypharmacy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Aging</condition>
  <condition>Primary Hypothyroidism</condition>
  <condition>Interaction Drug Food</condition>
  <arm_group>
    <arm_group_label>Morning Levothyroxine Intake First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evening Levothyroxine Intake First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evening Levothyroxine Administration</intervention_name>
    <description>Bedtime levothyroxine intake, with 60-minute meal-free interval</description>
    <arm_group_label>Morning Levothyroxine Intake First</arm_group_label>
    <other_name>Bedtime Levothyroxine Administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morning Levothyroxine Administration</intervention_name>
    <description>Morning levothyroxine intake, 60 minutes before breakfast.</description>
    <arm_group_label>Evening Levothyroxine Intake First</arm_group_label>
    <other_name>Before Breakfast Levothyroxine Administration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals aged 60 years or older who consult at the Geriatrics, Endocrinology and
             Internal Medicine Clinic at Hospital Clinicas de Porto Alegre

          -  Patients diagnosed with Primary Hypothyroidism

          -  Patients on levothyroxine for at least 6 months

          -  Patients with the same dose of levothyroxine for at least 3 months

        Exclusion Criteria:

          -  Severe Dementia

          -  Severe Congestive Heart Failure (NYHA IV or / and three or more hospitalizations for
             heart failure within 1-year interval)

          -  Diagnosis of Advanced Stage Neoplasia

          -  Diagnosis of Thyroid Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Gorga Bandeira de Mello</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of the Post Graduate Program in Endocrinology at the Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renato Gorga Bandeira de Mello</last_name>
    <phone>555133596400</phone>
    <email>rgmello@hcpa.edu.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karina Karina Giassi</last_name>
    <phone>5551998088446</phone>
    <email>karinagiassi@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Gorga Bandeira de Mello</last_name>
      <phone>5133598152.</phone>
      <email>rgmello@hcpa.edu.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polypharmacy</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

